All Companies


3D Bio Corporation
De­vel­op­ing scal­able bio­print­ed car­ti­lage ther­a­peu­tics to ad­dress un­met med­i­cal needs in re­con­struc­tive and or­tho­pe­dic surgery. Fil­ing IND for or­phan in­di­ca­tions end of 2017. [more in­for­ma­tion]
4D Molecular Therapeutics
De­vel­op­ing the Di­rect­ed Ther­a­peu­tic Vec­tor Evo­lu­tion plat­form of nov­el AAV vec­tors to de­liv­er genes to any tis­sue or or­gan in the body. In con­trast to first-gen­er­a­tion vec­tors, 4D's cus­tomized... [more in­for­ma­tion]
Abide Tx
Abide’s plat­form ex­ploits the pow­er of che­mo­pro­teomics to mine the serine hy­dro­lase su­per­fam­i­ly for nov­el drug tar­gets. Our plat­form in­cludes a pro­pri­e­tary chem­i­cal li­brary that is de­signed to... [more in­for­ma­tion]
Ablynx nv ABLX:BR
Nano­body plat­form with 8 com­pounds in its clin­i­cal pipe­line in ar­eas in­clud­ing aTTP, RA, SLE, RSV and I-O. Po­ten­tial for first pro­pri­e­tary prod­uct (ca­pla­cizumab) EU launch in 2018. Mul­ti­ple part­n­ers,... [more in­for­ma­tion]
Abpro
Ther­a­peu­tic anti­body com­pany tar­get­ing hu­man dis­ease. Through its core tech­nol­o­gy, the Di­ver­sIm­muneTM plat­form, Abpro lev­er­ages syn­thet­ic bi­ol­o­gy and im­munol­o­gy to gen­er­ate ther­a­peu­tic anti­bodies... [more in­for­ma­tion]
Accera, Inc.
Ad­dress­ing the metabolic de­fect fun­da­men­tal to the patho­phy­si­ol­o­gy of Alzheimer's Dis­ease. Lead com­pound in­duces ke­to­sis, sup­p­ly­ing an al­ter­na­tive en­er­gy source for the pro­gres­sive de­c­line in... [more in­for­ma­tion]
AcelRx Pharmaceuticals, Inc. ACRX
De­vel­op­ing DSU­VIA (ARX-04) - HCP ad­min­is­tered sufen­tanil nan­otab with op­por­tu­ni­ty in ER de­part­ments, am­bu­la­to­ry surgery cen­ters, and paramedic tran­s­ports; met all end­points in 2 piv­o­tal Ph 3 studies,... [more in­for­ma­tion]
Achillion Pharmaceuticals, Inc. ACHN
Pipe­line of com­ple­ment fac­tor D in­hibi­tors to treat rare dis­eas­es such as PNH and C3G. ACH-4471 in Ph 2 trials, with da­ta ex­pect­ed 1H2017. Short-du­ra­tion, pan-geno­typ­ic, oral treat­ment for HCV with... [more in­for­ma­tion]
Adamas Pharmaceuticals, Inc. ADMS
Fo­cused on de­vel­op­ing drugs for chron­ic neu­ro­log­i­cal di­s­or­ders by uti­l­iz­ing time-de­pen­dent bi­ol­o­gy to match ther­a­peu­tic drug pro­files with dis­ease pat­terns to drive a more sig­ni­f­i­cant durable ef­fect. [more in­for­ma­tion]
Adaptimmune Therapeutics PLC ADAP
Mul­ti­ple trials on­go­ing in both solid tu­mors and he­ma­to­log­ic can­cer types with pro­pri­e­tary T-cell en­gi­neer­ing plat­form. Da­ta read­out from NY-ESO SPEAR T-cells in NS­CLC and ovarian can­cer and da­ta from... [more in­for­ma­tion]
Affimed N.V. AFMD
En­gi­neer­ing NK cell and T-cell en­gag­ing bis­pe­cif­ic anti­bodies and Tris­pe­cif­ic Abs. Lead pro­gram AFM13(CD30/CD16A)in a Ph1b com­bo w/ Keytru­da for Hodgkins Lym­pho­ma. AFM13 - Ph2a monother­a­py for HL,... [more in­for­ma­tion]
Allecra Therapeutics
Al­le­cra Ther­a­peu­tics is fo­cused on ef­forts to com­bat antibi­ot­ic re­sis­tance. The com­pany's goal is to de­vel­op new treat­ments which over­come emerg­ing re­sis­tance mech­anisms, there­by sav­ing lives of... [more in­for­ma­tion]
Amarin Corporation AMRN
Fo­cused on the de­vel­op­ment and com­mer­cial­iza­tion of ther­a­peu­tics to im­prove car­dio­vas­cu­lar health. Vas­ce­pa is the first and on­ly pure EPA ome­ga-3 fat­ty acid ap­proved to low­er trig­lyc­eride lev­els in... [more in­for­ma­tion]
Anavex Life Sciences Corp. AVXL
Fo­cused on neu­rode­gen­er­a­tive and neu­rode­vel­op­men­tal dis­eas­es with lead can­di­date ANAVEX 2-73 in a Ph 2 trial. ANAVEX 2-73 is cur­rent­ly be­ing de­vel­oped for Alzheimer’s dis­ease, with broad­er... [more in­for­ma­tion]
AngioGenex AGGX
From MSKCC & Johns Hop­kins. De­vel­op­ing a small molecule, first-in-class Id-tar­get­ed an­ta­g­on­ist. Id is well-pub­lished, pre­vi­ous­ly "un­hit" tar­get. In­hibi­tor of Dif­fer­en­ti­a­tion (Id) pro­tein... [more in­for­ma­tion]
AntibioTX
Clin­i­cal stage, fo­cused on the de­vel­op­ment of their Tx-class antibi­otics plat­form. The Tx-class antibi­otics plat­form us­es its new mech­anism of ac­tion to treat bac­te­rial in­fec­tions and re­lat­ed... [more in­for­ma­tion]
Apricus Biosciences, Inc. APRI
Ad­vanc­ing medicines in urol­o­gy and rheu­ma­tol­o­gy, with two prod­uct can­di­dates in de­vel­op­ment. Fo­cused on U.S. ap­pro­val of Vi­taros, a top­i­cal gel for erec­tile dys­func­tion; NDA re-sub­mitt­ed in Q3 2017... [more in­for­ma­tion]
Aptamir, Inc.
[more in­for­ma­tion]
Aquinox Pharmaceuticals, Inc. AQXP
Dis­cov­er­ing and de­vel­op­ing tar­get­ed ther­a­peu­tics in in­flam­ma­tion and im­muno-on­col­o­gy. Lead as­set, AQX-1125, is an oral, once dai­ly, small molecule ac­ti­va­tor of SHIP1. AQX-1125 is cur­rent­ly in Ph3 for... [more in­for­ma­tion]
Arog
A pri­vate, clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany that has lev­er­aged its plat­form of benz­imi­da­zole deri­va­tives to de­vel­op a ro­bust drug pipe­line of oral­ly avai­l­able, po­tent, and se­lec­tive small... [more in­for­ma­tion]
Ascentage Pharma
As­cen­t­age Phar­ma is a Chi­na-based, glob­al-ori­ent­ed, clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany, ded­i­cat­ed to dis­cov­ery and de­vel­op­ment of the “first-in-class” and the... [more in­for­ma­tion]
Asklepion Pharmaceuticals
Pri­vate, fo­cused on the de­vel­op­ment of IV Cit­rul­line for rare pe­di­a­tric dis­eas­es. First in­di­ca­tion, the pre­ven­tion of sig­ni­f­i­cant se­que­lae of pe­di­a­tric acute car­diopul­mo­nary by­pass-in­duced lung... [more in­for­ma­tion]
Aurinia Pharmaceuticals, Inc. AUPH
A late stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on the de­vel­op­ment of its nov­el ther­a­peu­tic im­muno­mo­d­u­lat­ing drug can­di­date, vo­clos­porin, for the treat­ment of lu­pus nephri­tis. Our strat­e­gy is to... [more in­for­ma­tion]
AxoGen AXGN
Rev­enue gen­er­at­ing, ded­i­cat­ed to pe­ripher­al nerve re­pair with a port­fo­lio of re­gen­er­a­tive medicine prod­ucts avai­l­able in the US, Ca­na­da and sev­er­al other coun­tries. Prod­ucts in­clude Avance Nerve... [more in­for­ma­tion]
Bellicum Pharmaceuticals Inc. BLCM
De­vel­op­ing CAR T/TCR ther­a­pies with molec­u­lar switch tech­nol­o­gy and co-stim do­mains en­abling phar­ma­co­log­ic con­trol over cells for en­hanced safe­ty and ef­fi­ca­cy. Mul­ti­ple Ph 1/2 trials are un­der­way:... [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc BHVN
De­vel­op­ing a port­fo­lio of in­no­va­tive, late-stage prod­uct can­di­dates tar­get­ing neu­ro­log­i­cal dis­eas­es, in­clud­ing rare di­s­or­ders. Lead de­vel­op­ment pro­grams in­clude mul­ti­ple com­pounds across its CGRP... [more in­for­ma­tion]
BioPharmX BPMX
Der­ma­tol­o­gy-fo­cused, de­vel­op­ing BPX-01 for top­i­cal mino­cy­c­line acne and rosacea treat­ment, based on its nov­el hy­drophil­ic top­i­cal for­mu­la­tion tech­nol­o­gy. Re­port­ed Ph 2b da­ta with BPX-01 in acne. Phase... [more in­for­ma­tion]
Calyxt
Ca­lyxt is an Ag­biotech com­pany fo­cused on de­vel­op­ing crops with healthi­er char­ac­teris­tics. Cap­i­tal­iz­ing on its team and new tech­nolo­gies, the com­pany’s mis­sion is to de­vel­op a nov­el gen­er­a­tion... [more in­for­ma­tion]
Camurus AB CAMX:ST
De­vel­op­ing en­hanced prod­ucts by com­bin­ing pro­pri­e­tary Fluid­Crys­tal® for­mu­la­tion for sol­u­bi­l­iza­tion and sta­bi­l­iza­tion with ac­tive phar­ma­ceu­ti­cal sub­s­tances. Lead prod­uct CAM2038, for Opi­oid... [more in­for­ma­tion]
Catalyst Pharmaceuticals, Inc. CPRX
De­vel­op­ing Fir­dapse for the treat­ment of or­phan dis­ease in­di­ca­tion, Lam­bert-Ea­ton Myas­thenic Syn­drome (LEMS) with pos­i­tive Ph 3 da­ta and ad­di­tio­n­al Ph 3 trial re­sults ex­pect­ed in 2017. Al­so de­vel­op­ing... [more in­for­ma­tion]
Cellectis SA CLLS
Lead­er in en­gi­neered al­lo­gene­ic (off-the-shelf) CAR-T ther­a­peu­tics. Pipe­line in­cludes pro­pri­e­tary pro­grams and Pfiz­er and Servi­er part­n­er­ships on nu­mer­ous tar­gets in on­col­o­gy. Lead in­ter­nal pro­gram... [more in­for­ma­tion]
Chi-Med HCM
De­vel­op­ment pipe­line of eight nov­el late stage on­col­o­gy can­di­dates, with five Ph 3 trials un­der­way, fu­eled by its pro­f­itable Chi­nese com­mer­cial plat­form. Fruquin­tinib (VEG­FR in­hibi­tor, LLY-part­nered)... [more in­for­ma­tion]
Cibus
A com­mer­cial stage, pre­ci­sion gene edit­ing com­pany. Cibus' tech­nol­o­gy has ap­pli­ca­tions in non-GMO crop de­vel­op­ment, in­dus­trial biotech and hu­man health. The com­pany uti­l­izes Gene Re­pair... [more in­for­ma­tion]
CureVac AG
Cure­Vac's mR­NA tech­nol­o­gy is its use as a da­ta car­ri­er to in­struct the hu­man body to pro­duce its own pro­teins to tar­get can­cer ther­a­pies, pro­phy­lac­tic vaccines and molec­u­lar ther­a­pies. The... [more in­for­ma­tion]
CytomX Therapeutics, Inc. CTMX
Anti­body pro­drug (pro­body) plat­form se­lec­tive­ly en­hances anti­body bind­ing within the tu­mor mi­croen­vi­ron­ment, en­abling treat­ments de­signed to en­hance tu­mor tar­get­ing and wi­den the ther­a­peu­tic win­dow. [more in­for­ma­tion]
Enzo Biochem, Inc. ENZ
De­vel­op re­search tools, di­ag­nos­tics and ther­a­peu­tics and pro­vides ref­er­ence lab­o­ra­to­ry ser­vices to the med­i­cal com­mu­ni­ty. Ac­tiv­i­ties in­clude R&D, man­u­fac­tur­ing and mar­ket­ing of biomed­i­cal re­search... [more in­for­ma­tion]
Evotec AG EVTA:FF
EVT In­no­vate is an in­ter­nal drug dis­cov­ery plat­form with over 70 prod­uct op­por­tu­ni­ties and ex­per­tise across dis­eas­es ar­eas. In­no­vate is pro­gress­ing nov­el, first-in-class, pre-clin­i­cal as­sets to... [more in­for­ma­tion]
FivePrime Therapeutics FPRX
Five Prime Ther­a­peu­tics, Inc. dis­cov­ers and de­vel­ops in­no­va­tive ther­a­peu­tics to im­prove the lives of pa­tients with se­ri­ous dis­eas­es. Five Prime's com­pre­hen­sive dis­cov­ery plat­form, which... [more in­for­ma­tion]
Flex Pharma, Inc. FLKS
De­vel­op­ing in­no­va­tive and pro­pri­e­tary treat­ments for cramps and spasms as­so­ci­at­ed with the se­vere neu­ro­log­i­cal dis­eas­es of ALS, MS and pe­ripher­al neu­ro­pathies such as Char­cot-Marie-Tooth (CMT) based... [more in­for­ma­tion]
Forward Pharma A/S FWP
The Com­pany owns a sig­ni­f­i­cant in­tel­lec­tu­al prop­er­ty (IP) port­fo­lio re­lat­ed to DMF for­mu­la­tions, to which it grant­ed Bio­gen an ir­re­vo­ca­ble li­cense to all of its IP through the re­cent Li­cense Agree­ment... [more in­for­ma­tion]
Genfit SA GNFTF
Lead pro­gram Ela­fi­branor (GFT505) in Phase 3 trials for NASH. Ela­fi­branor is a PPAR al­pha/del­ta ag­on­ist cur­rent­ly in a Ph 3 trial with com­ple­tion of en­roll­ment for in­ter­im look ex­pect­ed 1Q18. On­go­ing... [more in­for­ma­tion]
GenSight Biologics SIGHT.PA
Gene ther­a­pies for se­vere reti­nal and CNS de­gen­er­a­tive patholo­gies. Lead prod­uct, GS010, is in Ph3 for the treat­ment of Le­ber Hered­i­tary Op­tic Neu­ro­pa­thy (LHON) with da­ta ex­pect­ed in 2018. Pipe­line... [more in­for­ma­tion]
Geron Corporation GERN
De­vel­op­ing ime­tel­s­tat (a telom­erase in­hibi­tor) for the treat­ment of he­ma­to­log­ic ma­lig­nan­cies. Ime­tel­s­tat is be­ing eval­u­at­ed in an on­go­ing Phase II trial (IM­bark) in re­lapsed/re­frac­to­ry MF, and a Phase... [more in­for­ma­tion]
Inspirion Delivery Sciences LLC
Pri­vate­ly held spec. phar­ma co ded­i­cat­ed to ad­vanc­ing so­lu­tions in the field of pre­scrip­tion drug abuse de­ter­rence. U.S. Rights for Mor­phaBond ER™ and Rox­y­Bond™ li­censed to Daiichi Sankyo,... [more in­for­ma­tion]
Loxo Oncology, Inc. LOXO
De­vel­ops tar­get­ed drugs for the treat­ment of can­cer in ge­net­i­cal­ly defined pa­tient pop­u­la­tions. Lead pro­gram: pur­pose built pan TRK in­hibi­tor in a Ph 2 solid tu­mor study with FDA break­through... [more in­for­ma­tion]
Medigene AG MDGEF
Im­muno-on­col­o­gy com­pany fo­cused on per­so­n­al­ized T cell-based ther­a­pies. MDG1011, TCR tar­get­ing PRAME anti­gen, to en­ter clin­ic in 2H17 for bas­ket of he­ma­to­log­i­cal in­di­ca­tions (AML, MDS and MM). [more in­for­ma­tion]
MedinCell
Pro­f­itable clin­i­cal stage plat­form tech­nol­o­gy drug de­liv­ery com­pany fo­cused on long-act­ing in­jectable for­mu­la­tions for sub­cu­ta­neous de­liv­ery in­jec­tion to pro­vide sys­temic ef­fect while min­i­miz­ing... [more in­for­ma­tion]
Medivir AB MVIR-B.SE
Re­cent­ly an­nounced to­p­line da­ta from Ph 2 study of MIV-711, a cathepsin K in­hibi­tor for mod­er­ate knee os­teoarthri­tis, de­mon­s­trat­ing MIV-711 has a dis­ease mod­i­fy­ing ef­fect on knee struc­ture. Broad... [more in­for­ma­tion]
MEI Pharma, Inc. MEIP
Clin­i­cal on­col­o­gy com­pany fo­cused on the de­vel­op­ment of nov­el small molecules for the treat­ment of can­cer. Lead prod­uct Pra­ci­no­s­tat is a late clin­i­cal stage oral HDAC for the treat­ment of AML and MDS. [more in­for­ma­tion]
MorphoSys AG MPSYF
Clin­i­cal stage anti­body co. with dense pipe­line of >100 prod­ucts in mul­ti­ple stages/in­di­ca­tions. First part­n­er prod­uct on mar­ket (JNJ; Trem­fya for mod­er­ate to se­vere pso­ri­a­sis). Pro­pri­e­tary pro­gram... [more in­for­ma­tion]
Motif Bio plc MTFB
Ph 3 antibi­ot­ic com­pany (pos­i­tive da­ta an­nounced; NDA fil­ing 1Q18) fo­cused on life-threat­en­ing in­fec­tions caused by mul­ti-drug re­sis­tant bac­te­ria. To­p­line re­sults with Iclaprim in pa­tients with acute... [more in­for­ma­tion]
Naia Pharma
De­vel­op­ing a long-act­ing GLP-1 ag­on­ist ( XTEN™-GLP-1) for Short Bow­el Syn­drome, which has or­phan drug sta­tus. Ex­pects to ini­ti­ate re­cruit­ment the P1b study in 1H17, and file an NDA by the fourth... [more in­for­ma­tion]
Nanobiotix SA NANO.PA
De­vel­op­ing first in class nano­par­ti­cle-based ra­dio-en­hancer NBTXR3 for soft tis­sue sar­co­ma, head and neck, liv­er, pros­tate, rec­tal and other can­cers. Al­so be­ing de­vel­oped for in si­tu vac­ci­na­tion in... [more in­for­ma­tion]
NexImmune, Inc.
Pri­vate IO com­pany de­vel­op­ing a unique ap­proach to anti­gen-spe­cif­ic T cell ther­a­py. Tech­nol­o­gy us­es syn­thet­ic nano­par­ti­cles de­c­o­rat­ed with a com­bi­na­tion of mul­ti­ple tu­mor rel­e­vant anti­gens and... [more in­for­ma­tion]
Nordic Nanovector ASA NANO.OL
Fo­cused on de­vel­op­ment of Anti­body-Ra­dionu­clide-Con­ju­gates (ARC). Lead as­set Be­ta­lutin, a nov­el an­ti-CD37 ARC (Luteti­um-177) ra­dioim­munother­a­peu­tic for the treat­ment of Non-Hodgkin Lym­pho­ma, en­ter­ing... [more in­for­ma­tion]
Novus Therapeutics NVUS
Novus Ther­a­peu­tics is a de­vel­op­ment stage phar­ma­ceu­ti­cal com­pany fo­cused on the de­vel­op­ment of prod­ucts for di­s­or­ders of the ear, nose, and throat (ENT). Novus has two tech­nolo­gies, each of which has... [more in­for­ma­tion]
OncoMed Pharmaceuticals OMED
a clin­i­cal-stage com­pany dis­cov­er­ing and de­vel­op­ing nov­el an­ti-can­cer ther­a­peu­tics. On­coMed is ad­vanc­ing its im­muno-on­col­o­gy R&D pipe­line, in­clud­ing an­ti-TIG­IT, whol­ly-owned GITRL-Fc trimer, and... [more in­for­ma­tion]
Oncopeptides AB ONCO:ST
De­vel­op­ing Yga­lo (melflufen), a next gen­er­a­tion alky­la­tor that pref­er­en­tial­ly tar­gets can­cer cells via pep­ti­dase tar­get­ing, for mul­ti­ple myelo­ma. Yga­lo over­comes re­sis­tance mech­anisms that im­pact... [more in­for­ma­tion]
Oncorus
On­corus is an ear­ly-stage biotech­nol­o­gy com­pany de­vel­op­ing po­tent on­co­lyt­ic im­munother­a­pies for can­cer. On­corus oHSV is con­trolled by cer­tain mi­cro-RNAs (miR­NAs) that are pre­sent in healthy cells, but... [more in­for­ma­tion]
Oryzon Genomics ORY:MA
De­vel­ops per­so­n­al­ized ther­a­peu­tics for pa­tients with can­cers or neu­rode­gen­er­a­tive di­s­or­ders. The com­pany’s lead com­pound, ORY-1001, is a high­ly po­tent LS­D1 in­hibi­tor cur­rent­ly in Ph 1/2a... [more in­for­ma­tion]
PAION AG PAIOF
Fo­cused on anes­th­e­sia around game chang­ing as­set Remi­ma­zo­lam, a short-act­ing anes­thet­ic. Remi­ma­zo­lam com­plet­ed a pos­i­tive Ph 3 in pro­ce­du­ral se­da­tion in the US. Pos­i­tive safe­ty da­ta in ASA III/IV... [more in­for­ma­tion]
PharmaMar SA PHM.MC
On­col­o­gy-fo­cused com­pany with 1H17 to­tal rev­enues of &eu­ro;96.9M. Yon­delis, for soft tis­sue sar­co­ma and ovarian can­cer, is com­mer­cial­ized in 75+ coun­tries, di­rect sales-force in Eu­rope, part­n­er­ship in... [more in­for­ma­tion]
Pharming Group NV PHARM.AS
GMP-com­pliant, vali­dat­ed plat­form that pro­duces high qual­i­ty re­com­bi­nant hu­man pro­tein more eco­nom­i­cal­ly than all other cur­rent tech­nolo­gies. Lead RU­CON­EST is an rhC1-es­terase in­hibi­tor ap­proved to... [more in­for­ma­tion]
PhaseBio Pharmaceuticals, Inc.
Clin­i­cal-stage, de­vel­op­ing new and im­proved bio­ther­a­peu­tics for the treat­ment of or­phan dis­eas­es, with an ini­tial fo­cus on car­diopul­mo­nary di­s­or­ders. Pro­pri­e­tary tech­nol­o­gy plat­form us­es re­com­bi­nant... [more in­for­ma­tion]
Photocure ASA PHCUF
Urol­o­gy-fo­cused spec-phar­ma. Hexvix®/Cysview® on mar­ket for the de­tec­tion and ma­n­age­ment of blad­der can­cer. Com­mer­cial­ized us­ing Co’s spe­cial­ist sales­force in Nordic and US; part­nered in... [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. PIRS
De­vel­op­ing an­ti­calins (re­com­bi­nant pro­teins dif­fer­en­ti­at­ed from MAbs) for can­cer, se­vere asth­ma and ane­mia. PRS-080, lead hep­cidin an­ta­g­on­ist for ane­mia to en­roll mul­ti-dose Phase 2a pa­tients in 2017. [more in­for­ma­tion]
Pliant Therapeutics, Inc.
By har­ness­ing the ther­a­peu­tic po­ten­tial of in­te­grin bi­ol­o­gy and TGF-be­ta mo­d­u­la­tion, Pliant aims to pre­vent or even re­v­erse fi­bro­sis to ad­dress the needs of many pa­tients. The com­pany al­so aims to... [more in­for­ma­tion]
Poxel SA POXEL:PA
De­vel­op­ing safer and more ef­fec­tive ther­a­pies for metabolic dis­eas­es. Imeglimin (a mi­to­chon­dria-based MOA) for Type 2 di­a­betes is Ph 3 ready in the US and EU, pre­vi­ous­ly meet­ing glycemic end­points in... [more in­for­ma­tion]
Prima BioMed PBMD
Aus­tralian-based, mar­ket lead­er de­vel­op­ing LAG-3 in im­muno-on­col­o­gy. CMO/CSO Fr&ea­cute;d&ea­cute;ric Trie­bel dis­cov­ered the LAG-3 gene in 1990 and iden­ti­fied the func­tions and med­i­cal ap­pli­ca­tions of... [more in­for­ma­tion]
Probiodrug AG PRBGF
De­vel­op­ing prod­ucts for treat­ment of Alzheimer’s Dis­ease (AD). An­nounced pos­i­tive da­ta in June 2017 from the Ph 2a (SAPHIR) clin­i­cal trial for PQ912, a first in class small molecule QC... [more in­for­ma­tion]
ProQR Therapeutics NV PRQR
Trans­for­ma­tive RNA medicines for the treat­ment of se­vere or­phan dis­eas­es such as CF and LCA Type 10, based on pro­pri­e­tary RNA re­pair plat­form tech­nolo­gies. Pro­QR's lead clin­i­cal pro­gram, QR-010,... [more in­for­ma­tion]
Protagonist Therapeutics PTGX
Pro­ta­g­on­ist uti­l­izes a pro­pri­e­tary pep­tide tech­nol­o­gy plat­form to de­vel­op first-in-class oral tar­get­ed ther­a­py-based drugs that work by block­ing bi­o­log­i­cal path­ways that are cur­rent­ly tar­get­ed by... [more in­for­ma­tion]
Protalix BioTherapeutics PLX
De­vel­op­ing “bio­bet­ters” us­ing a pro­pri­e­tary plant cell ex­pres­sion tech­nol­o­gy. First prod­uct Elely­so was ap­proved for Gauch­er dis­ease and WW rights ex­clud­ing Brazil were sold to Pfiz­er. [more in­for­ma­tion]
Pulse Biosciences, Inc. PLSE
A de­vel­op­ment-stage med­i­cal de­vice com­pany us­ing a nov­el and pro­pri­e­tary plat­form tech­nol­o­gy called Nano-Pulse Elec­tro-Sig­nal­ing or NPES. NPES is a lo­cal and drug-free tech­nol­o­gy that uti­l­izes... [more in­for­ma­tion]
RedHill Biopharma RDHL
Fo­cused on the de­vel­op­ment and com­mer­cial­iza­tion of small molecule drugs for the treat­ment of in­flam­ma­to­ry and gas­troin­testi­nal dis­eas­es, in­clud­ing can­cer. Three com­pounds in Ph3 de­vel­op­ment, RHB-105... [more in­for­ma­tion]
ReNeuron Group plc RENE:LN
Clin­i­cal-stage, UK-based cell ther­a­py com­pany with dif­fer­en­ti­at­ed al­lo­gene­ic off-the-shelf can­di­dates: chron­ic stroke dis­a­bil­i­ty (Ph3 ready, ini­ti­a­tion ear­ly 2018); re­tini­tis pig­men­tosa (RP, Ph1/2... [more in­for­ma­tion]
Rigel Pharmaceuticals RIGL
Rigel's lead prod­uct can­di­date is fos­ta­ma­tinib (Ta­valisse) for the treat­ment of chron­ic and per­sis­tent im­mune throm­bo­cy­tope­nia (ITP). On Oc­to­ber 2, 2017, the FDA in­di­cat­ed that it is not plan­n­ing... [more in­for­ma­tion]
Savara Inc. SVRA
De­vel­ops in­ha­la­tion ther­a­pies for the treat­ment of pa­tients with rare pul­mo­nary con­di­tions. Three pipe­line prod­ucts: Mol­gradex, an in­haled ne­b­u­l­ized GM-CSF to treat Pul­mo­nary Alve­o­lar Pro­tei­no­sis... [more in­for­ma­tion]
Stemline Therapeutics, Inc. STML
Three clin­i­cal stage prod­uct can­di­dates. SL-401, an IL-3/CD123 tar­get­ed ther­a­py for BPD­CN, com­plet­ed re­cruit­ment of its piv­o­tal Ph 2 has Break­through Desig­na­tion for the treat­ment of pa­tients with... [more in­for­ma­tion]
STRATEC Biomedical AG SBS.DE
Mar­ket lead­er in au­to­ma­tion sys­tems and soft­ware for the di­ag­nos­tics in­dus­try. In­s­talled base of >13,000 sys­tems across 20 fam­i­lies in­clud­ing PAN­THER (Ho­log­ic), Li­a­son XL (Di­a­Sorin), VI­DAS... [more in­for­ma­tion]
Strongbridge Biopharma SBBP
Strong­bridge is a com­mer­cial-stage com­pany fo­cused on ther­a­pies for rare dis­eas­es. Launched KEVEYIS for pe­ri­od­ic par­tial paral­y­sis in April 2017 in the US. Lead clin­i­cal as­set RE­COR­LEV is in Phase 3... [more in­for­ma­tion]
Sutro Biopharma
Fo­cused on de­vel­op­ing next gen­er­a­tion anti­body drug con­ju­gates (ADCs) and mul­ti-spe­cif­ic anti­body-based ther­a­peu­tics for can­cer ther­a­py. The com­pany’s dis­cov­ery and de­vel­op­ment ef­forts are... [more in­for­ma­tion]
Symic Bio
De­vel­op­ing a new ther­a­peu­tic cat­e­go­ry of bio­con­ju­gates that di­rect­ly tar­get the ex­tra­cel­lu­lar ma­trix (ECM). Two clin­i­cal Phase 1/2a can­di­dates which in­clude crit­i­cal limb is­chemia (SB-030) and dis­ease... [more in­for­ma­tion]
Taiwan Liposome Company (TLC)
A lead­ing Tai­wan bio­phar­ma­ceu­ti­cal com­pany fo­cused on R&D and com­mer­cial­iza­tion of in­no­va­tive pain ma­n­age­ment, oph­thal­mol­o­gy, and on­col­o­gy prod­ucts based on its pro­pri­e­tary lipid-based de­liv­ery... [more in­for­ma­tion]
Targovax TRVX:OS
De­vel­op­ing two com­ple­men­tary ap­proach­es: a pep­tide-based im­munother­a­py plat­form for pa­tients with RAS-mu­tat­ed can­cers and a virus-based im­munother­a­py plat­form based on en­gi­neered on­co­lyt­ic virus­es... [more in­for­ma­tion]
TCR2 Therapeutics
Pro­pri­e­tary TRuC™ plat­form based on T cell re­cep­tor fu­sion con­structs that em­ploy the full sig­nal­ing pow­er of the T cell re­cep­tor (TCR). This cell ther­a­py ap­proach al­lows per­sis­tent killing of... [more in­for­ma­tion]
Tessa Therapeutics
Clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on the treat­ment of can­cer by redi­rect­ing the body’s po­tent an­ti-vi­ral im­mune re­sponse to rec­og­nize and kill can­cer cells. Tes­sa’s core... [more in­for­ma­tion]
TiGenix NV TIG
De­vel­op­ing ther­a­pies for se­ri­ous med­i­cal con­di­tions by ex­ploit­ing the an­ti-in­flam­ma­to­ry prop­er­ties of al­lo­gene­ic, stem cells. Lead prod­uct, Cx601 for the treat­ment of com­plex pe­ria­nal fis­tu­las, has... [more in­for­ma­tion]
Tocagen Inc. TOCA
Can­cer-se­lec­tive gene ther­a­py com­pany. Lead pro­gram To­ca 511 and To­ca FC are be­ing studied in a reg­is­tra­tio­n­al Ph 2/3 trial for re­cur­rent high grade glio­ma (rHGG). A Ph 1 study of To­ca 511 and To­ca FC... [more in­for­ma­tion]
Vericel Corporation VCEL
Cam­bridge-based, mar­kets three au­tol­o­gous cell ther­a­py prod­ucts in the US. In 1Q 2017, com­menced MA­CI launch ac­tiv­i­ties and an­nounced treat­ment of the first pa­tient on Fe­bruary 1. An­nounced FDA Fast... [more in­for­ma­tion]
Veru Healthcare VERU
De­vel­op­ing and com­mer­cial­iz­ing phar­ma­ceu­ti­cals and de­vices in urol­o­gy and on­col­o­gy. Uti­l­izes the 505(b)2 path­way for more eco­nom­i­cal and fast-track ap­pro­val pro­cess­es. Prod­uct can­di­dates are for BPH,... [more in­for­ma­tion]
Vital Therapies, Inc. VTL
Vi­tal Ther­a­pies, Inc. is a bio­ther­a­peu­tic com­pany de­vel­op­ing a cell-based ther­a­py tar­get­ing the treat­ment of acute forms of liv­er fail­ure. The Com­pany's ELAD Sys­tem is an ex­tra­cor­po­re­al hu­man... [more in­for­ma­tion]
vTv Therapeutics, Inc. VTVT
Late-stage, next Ph. 3 Alzheimer's da­ta read-out af­ter AX­ON. Azeli­ra­gon - oral, small-molecule in­hibi­tor of the Re­cep­tor for Ad­vanced Gly­ca­tion End­prod­ucts (RAGE), lies up­stream to AD patholo­gies... [more in­for­ma­tion]
Wave Life Sciences Ltd. WVE
Wave is a clin­i­cal stage biotech com­pany fo­cused on de­liv­er­ing trans­for­ma­tio­n­al ther­a­pies for pa­tients with se­ri­ous, ge­net­i­cal­ly-defined dis­eas­es. Its chem­istry plat­form en­ables the cre­a­tion of high­ly... [more in­for­ma­tion]
Wilson Therapeutics WTX:ST
De­vel­op­ing nov­el ther­a­pies for pa­tients with rare dis­eas­es, with plans to start a piv­o­tal Ph 3 trial in ear­ly 2018 with WTX101, a first in class agent for Wil­son Dis­ease - a ge­net­ic con­di­tion... [more in­for­ma­tion]
ZAI Laboratory ZLAB
Zai Lab is a Shang­hai-based in­no­va­tive bio­phar­ma­ceu­ti­cal com­pany fo­cused on bring­ing trans­for­ma­tive medicines for can­cer, au­toim­mune and in­fec­tious dis­eas­es to pa­tients in Chi­na and around the world. [more in­for­ma­tion]